加拿大最新的年度总死亡数据来了，病毒变弱疫苗普及的2021/2022新增死亡1.7万，20年来最高！ Canada: number of deaths 2022 | Statista 2021／2022的意思是2021下半年到2022上半年，病毒变弱疫苗普及的一年，比病毒强劲没有疫苗的2020／2021，多死1.7万。 病毒强劲没有疫苗的2020／2021，比基本无疫情的2019／2020，…
Loading...
:
还说了打针很有效。。。。“由于社区的疫苗接种覆盖率如此之高，因此住院或重症监护病房 (ICU) 的 COVID-19 患者中有很大一部分现在接种了两剂或三剂疫苗。” 这句不好理解。
:
:
Follow the evidence, wherever it leads
https://www.youtube.com/watch?v=rfyOihhAD4A
Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database
Purpose
To evaluate the difference in mortality,
Patients treated with ivermectin
Patients treated with remdesivir
44 healthcare organizations and 68 million patients from US,
January 1, 2020 and July 11, 2021
Methods & Materials
Retrospectively identified diagnosed adults
Recorded use of ivermectin, but not remdesivir
Recorded use of remdesivir, but not ivermectin
Controlled for, comorbidities, and treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use.
Primary outcome assessed, mortality
Sith significance assessed at p less than 0.05.
Result
41,608 patients who had COVID-19
Treated with ivermectin n = 1,072
Treated with remdesivir n = 40,536
Ivermectin was associated with reduced mortality vs remdesivir
OR 0.308
p less than 0.0001.
Conclusion
Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir.
In the future, if more publications are published with the similar result to the current analyses, the certainty of evidence will increase.
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching (Brazil)
https://www.cureus.com/articles/82162...
Background
Ivermectin has demonstrated different mechanisms of action, coronavirus infection and COVID-19-related comorbidities.
Prophylaxis combined with the known safety profile of ivermectin
Study to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.
Prospective, July 2020 and December 2020
Inviting the entire population of Itajaí to a medical visit to enroll in the program,
ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day.
Study analysis consisted of comparing ivermectin users with non-users using cohorts
Results
223,128 citizens of Itajaí considered
159,561 included in the analysis
113,845 (71.3%) regular ivermectin users
45,716 (23.3%) non-users
Of these
4,311 ivermectin users were infected, (3.7% infection rate)
3,034 non-users (6.6% infection rate)
A 44% reduction in COVID-19 infection rate
Risk ratio (RR), 0.56
The regular use of ivermectin led to a 68% reduction in COVID-19 mortality
Deaths
25 (0.8%) deaths in the ivermectin group
79 (2.6%) among ivermectin non-users
RR, 0.32
p less than 0.0001
When adjusted for residual variables, reduction in mortality rate was 70%
There was a 56% reduction in hospitalization rate
44 in the ivermectin group
99 in non ivermectin users
After adjustment for residual variables, reduction in hospitalization rate was 67%
p less than 0.0001
Conclusion
In this large study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.
:
:
:
:
:
:
